Meeting the 12 Lymph Node (LN) benchmark in colon cancer

A. Rajput*, D. Romanus, M. R. Weiser, A. Ter Veer, J. Niland, J. Wilson, J. M. Skibber, Y. N. Wong, Al B Benson III, C. C. Earle, D. Schrag

*Corresponding author for this work

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Examining ≥12 LN in colon cancer has been suggested as a quality metric. The purpose of this study was to determine whether the 12 LN benchmark is achieved at NCCN centers compared to a US population-based sample. Methods: Patients with stage I-III disease resected at NCCN centers were identified from a prospective database (n=718) and were compared to 12,845 stage I-III patients diagnosed in a SEER region. Age, gender, location, stage, number of positive nodes were compared for NCCN and SEER data in regards to number of nodes evaluated. Multivariate logistic regression models were developed to identify factors associated with evaluating 12 LNs. Results: 92% of NCCN and 58% of SEER patients had ≥12 LN evaluated. For patients treated at NCCN centers, factors associated with not meeting the 12 LN target were left-sided tumors, stage I disease and BMI >30. Conclusions: ≥12 LN are almost always evaluated in NCCN patients. In contrast, this target is achieved in 58% of SEER patients. With longer follow-up of the NCCN cohort we will be able to link this quality metric to patterns of recurrence and survival and thereby better understand whether increasing the number of nodes evaluated is a priority for cancer control.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalJournal of surgical oncology
Volume102
Issue number1
DOIs
StatePublished - Jul 1 2010

Fingerprint

Benchmarking
Colonic Neoplasms
Lymph Nodes
Logistic Models
Neoplasms
Databases
Recurrence
Survival
Population

Keywords

  • Colon cancer
  • Lymph nodes
  • Outcomes

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Rajput, A., Romanus, D., Weiser, M. R., Ter Veer, A., Niland, J., Wilson, J., ... Schrag, D. (2010). Meeting the 12 Lymph Node (LN) benchmark in colon cancer. Journal of surgical oncology, 102(1), 3-9. https://doi.org/10.1002/jso.21532
Rajput, A. ; Romanus, D. ; Weiser, M. R. ; Ter Veer, A. ; Niland, J. ; Wilson, J. ; Skibber, J. M. ; Wong, Y. N. ; Benson III, Al B ; Earle, C. C. ; Schrag, D. / Meeting the 12 Lymph Node (LN) benchmark in colon cancer. In: Journal of surgical oncology. 2010 ; Vol. 102, No. 1. pp. 3-9.
@article{61a9c4eaf9fb42888e0f313c3f44a2aa,
title = "Meeting the 12 Lymph Node (LN) benchmark in colon cancer",
abstract = "Background: Examining ≥12 LN in colon cancer has been suggested as a quality metric. The purpose of this study was to determine whether the 12 LN benchmark is achieved at NCCN centers compared to a US population-based sample. Methods: Patients with stage I-III disease resected at NCCN centers were identified from a prospective database (n=718) and were compared to 12,845 stage I-III patients diagnosed in a SEER region. Age, gender, location, stage, number of positive nodes were compared for NCCN and SEER data in regards to number of nodes evaluated. Multivariate logistic regression models were developed to identify factors associated with evaluating 12 LNs. Results: 92{\%} of NCCN and 58{\%} of SEER patients had ≥12 LN evaluated. For patients treated at NCCN centers, factors associated with not meeting the 12 LN target were left-sided tumors, stage I disease and BMI >30. Conclusions: ≥12 LN are almost always evaluated in NCCN patients. In contrast, this target is achieved in 58{\%} of SEER patients. With longer follow-up of the NCCN cohort we will be able to link this quality metric to patterns of recurrence and survival and thereby better understand whether increasing the number of nodes evaluated is a priority for cancer control.",
keywords = "Colon cancer, Lymph nodes, Outcomes",
author = "A. Rajput and D. Romanus and Weiser, {M. R.} and {Ter Veer}, A. and J. Niland and J. Wilson and Skibber, {J. M.} and Wong, {Y. N.} and {Benson III}, {Al B} and Earle, {C. C.} and D. Schrag",
year = "2010",
month = "7",
day = "1",
doi = "10.1002/jso.21532",
language = "English (US)",
volume = "102",
pages = "3--9",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

Rajput, A, Romanus, D, Weiser, MR, Ter Veer, A, Niland, J, Wilson, J, Skibber, JM, Wong, YN, Benson III, AB, Earle, CC & Schrag, D 2010, 'Meeting the 12 Lymph Node (LN) benchmark in colon cancer', Journal of surgical oncology, vol. 102, no. 1, pp. 3-9. https://doi.org/10.1002/jso.21532

Meeting the 12 Lymph Node (LN) benchmark in colon cancer. / Rajput, A.; Romanus, D.; Weiser, M. R.; Ter Veer, A.; Niland, J.; Wilson, J.; Skibber, J. M.; Wong, Y. N.; Benson III, Al B; Earle, C. C.; Schrag, D.

In: Journal of surgical oncology, Vol. 102, No. 1, 01.07.2010, p. 3-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Meeting the 12 Lymph Node (LN) benchmark in colon cancer

AU - Rajput, A.

AU - Romanus, D.

AU - Weiser, M. R.

AU - Ter Veer, A.

AU - Niland, J.

AU - Wilson, J.

AU - Skibber, J. M.

AU - Wong, Y. N.

AU - Benson III, Al B

AU - Earle, C. C.

AU - Schrag, D.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Background: Examining ≥12 LN in colon cancer has been suggested as a quality metric. The purpose of this study was to determine whether the 12 LN benchmark is achieved at NCCN centers compared to a US population-based sample. Methods: Patients with stage I-III disease resected at NCCN centers were identified from a prospective database (n=718) and were compared to 12,845 stage I-III patients diagnosed in a SEER region. Age, gender, location, stage, number of positive nodes were compared for NCCN and SEER data in regards to number of nodes evaluated. Multivariate logistic regression models were developed to identify factors associated with evaluating 12 LNs. Results: 92% of NCCN and 58% of SEER patients had ≥12 LN evaluated. For patients treated at NCCN centers, factors associated with not meeting the 12 LN target were left-sided tumors, stage I disease and BMI >30. Conclusions: ≥12 LN are almost always evaluated in NCCN patients. In contrast, this target is achieved in 58% of SEER patients. With longer follow-up of the NCCN cohort we will be able to link this quality metric to patterns of recurrence and survival and thereby better understand whether increasing the number of nodes evaluated is a priority for cancer control.

AB - Background: Examining ≥12 LN in colon cancer has been suggested as a quality metric. The purpose of this study was to determine whether the 12 LN benchmark is achieved at NCCN centers compared to a US population-based sample. Methods: Patients with stage I-III disease resected at NCCN centers were identified from a prospective database (n=718) and were compared to 12,845 stage I-III patients diagnosed in a SEER region. Age, gender, location, stage, number of positive nodes were compared for NCCN and SEER data in regards to number of nodes evaluated. Multivariate logistic regression models were developed to identify factors associated with evaluating 12 LNs. Results: 92% of NCCN and 58% of SEER patients had ≥12 LN evaluated. For patients treated at NCCN centers, factors associated with not meeting the 12 LN target were left-sided tumors, stage I disease and BMI >30. Conclusions: ≥12 LN are almost always evaluated in NCCN patients. In contrast, this target is achieved in 58% of SEER patients. With longer follow-up of the NCCN cohort we will be able to link this quality metric to patterns of recurrence and survival and thereby better understand whether increasing the number of nodes evaluated is a priority for cancer control.

KW - Colon cancer

KW - Lymph nodes

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=77954105801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954105801&partnerID=8YFLogxK

U2 - 10.1002/jso.21532

DO - 10.1002/jso.21532

M3 - Article

C2 - 20578172

AN - SCOPUS:77954105801

VL - 102

SP - 3

EP - 9

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -

Rajput A, Romanus D, Weiser MR, Ter Veer A, Niland J, Wilson J et al. Meeting the 12 Lymph Node (LN) benchmark in colon cancer. Journal of surgical oncology. 2010 Jul 1;102(1):3-9. https://doi.org/10.1002/jso.21532